Validation of the antifactor Xa and antifactor IIa assays for the potency assessment of nadroparin in pharmaceutical formulations

The low-molecular weight heparin nadroparin calcium is used clinically for the prevention and treatment of venous and arterial thrombosis. The antifactor Xa and antifactor IIa assays were validated by investigating the parameters of range, linearity (r2 = 0.9905 and r2 = 0.9914, respectively) precis...

Full description

Saved in:
Bibliographic Details
Published in:Journal of AOAC International 2006, Vol.89 (1), p.58-64
Main Authors: DALMORA, Sérgio Luiz, SILVA SANGOI, Maximiliano Da, BARTH, Thiago, BRUM, Liberato, FERREIRA VACCARI, Silvana
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Calibration
Cattle
Chemical properties
Chemistry Techniques, Analytical - methods
Chemistry, Pharmaceutical - methods
Drugs
Evaluation
Factor Xa - analysis
Factor Xa - chemistry
Food industries
Fundamental and applied biological sciences. Psychology
Health aspects
Heparin
Humans
Nadroparin - analysis
Nadroparin - chemistry
Product/Service Evaluations
Prothrombin - analysis
Prothrombin - chemistry
Quality Control
Reproducibility of Results
Thrombosis - prevention & control
Time Factors
Venous Thrombosis - prevention & control
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The low-molecular weight heparin nadroparin calcium is used clinically for the prevention and treatment of venous and arterial thrombosis. The antifactor Xa and antifactor IIa assays were validated by investigating the parameters of range, linearity (r2 = 0.9905 and r2 = 0.9914, respectively) precision, accuracy, and robustness. The 2 methods incorporated a chromogenic endpoint and detection at 405 nm, yielding good results with detection limits of 0.004 and 0.01 IU/mL and quantitation limits of 0.01 and 0.03 IU/mL, respectively, for the antifactor Xa and antifactor IIa assays. Nadroparin calcium pharmaceutical products were evaluated by the antifactor Xa assay and the antifactor IIa assay, giving potencies between 93.86 and 109.88%, with an antifactor Xa/antifactor IIa ratio between 3.2 and 3.7. The results demonstrated the validity of the assays that are useful methodologies for the routine quality control of nadroparin in pharmaceutical formulations.
ISSN:1060-3271
1944-7922
DOI:10.1093/jaoac/89.1.58